Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia

被引:51
作者
Aouifi, A
Blanc, P
Piriou, V
Bastien, OH
Ffrench, P
Hanss, M
Lehot, JJ
机构
[1] Univ Lyon 1, Serv Anesthesie Reanimat, F-69365 Lyon, France
[2] Univ Lyon 1, EA 1896, F-69365 Lyon, France
[3] Hop Cardiovasc & Pneumol L Pradel, Hematol Lab, Lyon, France
关键词
D O I
10.1016/S0003-4975(00)02022-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The use of cardiopulmonary bypass (CPB) in patients with a history of type II heparin-induced thrombocytopenia (HIT) may be associated with complications related to their anticoagulation management. Methods. Between January 1997 and December 1999, among 4,850 adults patients who underwent cardiac surgery in our institution, 10 patients presented with preoperative type II HIT. In 4 patients, anticoagulation during CPB was achieved with danaparoid sodium. In 6 other patients, heparin sodium was used after pretreatment with epoprostenol sodium. Results. No significant change in platelet count occurred in any patient. No intraoperative thrombotic complication was encountered. Total postoperative chest drainage ranged from 250 to 1,100 mi in patients pretreated with epoprostenol and 1,700 to 2,470 mi in patients who received danaparoid sodium during CPB (p < 0.05, Mann-Whitney U test), Conclusions. During CPB, inhibition of platelet aggregation by prostacyclin may be a safe anticoagulation approach in patients with type II HIT. (C) 2001 by The Society of Thoracic Surgeons.
引用
收藏
页码:678 / 683
页数:6
相关论文
共 28 条
[1]  
ADDONIZIO VP, 1987, SURGERY, V102, P796
[2]  
AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95
[3]  
Bauer TL, 1997, CIRCULATION, V95, P1242
[4]   PULMONARY AND ANTIAGGREGATORY EFFECTS OF PROSTACYCLIN AFTER INHALATION AND INTRAVENOUS-INFUSION [J].
BURGHUBER, OC ;
SILBERBAUER, K ;
HABER, P ;
SINZINGER, H ;
ELLIOTT, M ;
LEITHNER, C .
RESPIRATION, 1984, 45 (04) :450-454
[5]  
DANHOF M, 1992, HAEMOSTASIS, V22, P73
[6]   HEPARIN-FREE CARDIOPULMONARY BYPASS - 1ST REPORTED USE OF HEPARINOID (ORG 10172) TO PROVIDE ANTICOAGULATION FOR CARDIOPULMONARY BYPASS [J].
DOHERTY, DC ;
ORTEL, TL ;
DEBRUIJN, N ;
GREENBERG, CS ;
VANTRIGT, P .
ANESTHESIOLOGY, 1990, 73 (03) :562-565
[7]  
GREINACHER A, 1994, THROMB HAEMOSTASIS, V71, P247
[8]   Recombinant hirudin (Lepirndin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia -: A prospective study [J].
Greinacher, A ;
Völpel, H ;
Janssens, U ;
Hach-Wunderle, V ;
Kemkes-Matthes, B ;
Eichler, P ;
Mueller-Velten, HG ;
Pötzsch, B .
CIRCULATION, 1999, 99 (01) :73-80
[9]   Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium [J].
Grocott, HP ;
Root, J ;
Berkowitz, SD ;
deBruijn, N ;
Landolfo, K .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1997, 11 (07) :875-877
[10]   FATAL THROMBOCYTOPENIC COAGULOPATHY AFTER CARDIOPULMONARY BYPASS - CLINICOPATHOLOGICAL CORRELATIONS IMPLICATING HEPARIN [J].
HECK, HA ;
LUTCHER, CL ;
FALLS, DG .
SOUTHERN MEDICAL JOURNAL, 1994, 87 (08) :789-793